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17.1 INTRODUCTION
 
During the last three decades, enzymology and enzyme technology have progressed considerably
and, as a result, there are many examples of industrial applications where enzymes, in the native
or immobilized form, are being used. These include food industry, materials processing, textiles,
detergents, biochemical and chemical industries, biotechnology, and pharmaceutical uses.
 
1
 
 The
overall impact of enzymes on industrial applications is, however, still quite limited due to their
relative instability under operational conditions, which may involve high temperatures, organic
solvents, and exposure to other denaturants. Various approaches, including, among others, addition
of additives,
 
2,3
 
 chemical modification,
 
4,5
 
 protein engineering,
 
6
 
 and enzyme immobilization,
 
1,7
 
 have
been assessed for their ability to increase the stability of enzymes toward heat or denaturants.
 
7,8
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The use of enzymes in medical applications has been less extensive as those for other types of
industrial applications. For example, pancreatic enzymes have been in use since the nineteenth
century for the treatment of digestive disorders. At present, the most successful applications of
enzymes in medicine are extracellular, such as topical uses, removal of toxic substances, and the
treatment of life-threatening disorders within the blood circulation.
 
9
 
 The production of therapeutic
enzymes has progressed, but the costs of enzyme production, isolation, and purification are still
too high to make them available for clinical applications. Furthermore, the ability to store unstable
enzymes for long periods of time is also a limitation for their more widespread use. Most appli-
cations in the biomedical field are still in the state of basic studies rather than definite applications,
owing to the absence of the necessary information on toxicology, hemolysis, allergenicity, immu-
nological reactions, and chemical stability of the system 
 
in vivo
 
.
 
9,10
 
This chapter will focus on the importance of using enzymes in medical applications and, in
particular, the use of immobilized enzymes. For that, some aspects of enzyme immobilization
technology, including the traditional physical and chemical methods and new immobilization
methodologies, based on biological and genetic engineering approaches, will be reviewed. Several
examples will be given of immobilized enzymes in various support materials and using different
immobilization strategies, according to the objective of their application in the biomedical field. 
 
17.2 ENZYMES IN MEDICINE
 
Since the mid-1950s there has been a considerable increase in both measurement of enzyme
activities and the use of purified enzymes in clinical practice. In recent years, many enzymes have
been isolated and purified, and this made it possible to use enzymes to determine the concentration
of substrates and products of clinical importance. A further development, arising from the increased
availability of purified enzymes, has been targeted to enzyme therapy.
 
17.2.1 C
 
LINICAL D
 
IAGNOSIS
 
The measurement of enzyme activities in serum is of major importance as an aid in diagnosis,
being used as means of monitoring progress after therapy, recovery after surgery, and detection of
transplant rejection. Urine can be also analyzed for determination of enzyme activities since the
detection of certain enzymes in urine may indicate kidney damage or failure.
 
11
 
 On the other hand,
the concentration of certain metabolites in serum or urine may be determined by enzymatic methods.
The method consists of using an enzyme to transform a metabolite into its product and then estimate
the amount of transformed substrate. The use of enzymatic methods presents several advantages,
such as the high specificity of the enzyme to estimate the concentration of the metabolite in the
presence of other substances, avoiding the need of purification steps prior to chemical analysis. In
addition, enzymatic reactions are performed at mild conditions, allowing the analysis of labile
compounds that would be degraded by harsher chemical methods. The cost of purified enzymes
may be, however, too high to support routine analysis, but the use of immobilized enzymes allows
for enzyme reuse and the application of immobilized enzymes for diagnostic assays and as bio-
sensors will be further discussed in Section 17.3.2.4 of this chapter. The determination of serum
metabolites in serum by enzymatic methods includes a wide range of substances such as glucose,
uric acid, urea, cholesterol, cholesterol esters, triglycerides, and creatine, among others.
 
11
17.2.2 E
 
NZYME T
 
HERAPY
 
Many inborn metabolic disorders are associated with the absence of activity of one particular
enzyme normally found in the body. Of the 1250 autosomal recessive human genetic diseases, over
200 involve errors in metabolism that result from specific known enzyme deficiencies.
 
12
 
 Table 17.1
lists some examples of inborn errors or disorders in metabolism due to enzyme deficiencies.
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The initial identification of the disease may be difficult to determine and normally requires a
tissue biopsy. For some genetic diseases, DNA probes are now available that can be used on small
amounts of blood, cells, or amniotic fluid. Albinism, for example, is often caused by the absence
of tyrosinase, an enzyme essential for the production of cellular pigments. Tyrosinase is a copper-
containing enzyme that catalyzes the first two rate-limiting steps in the melanin biosynthetic
pathway, the oxidation of tyrosine to dopa and the subsequent dehydrogenation of dopa to
dopaquinone. The human tyrosinase gene, encoding 529 amino acids, consists of five exons
spanning more than 50 Kb of DNA in chromosomes.
 
20
 
 When homozygous mutations of the tyrosine
gene result in complete absence of melanogenic activity, such a patient, categorized as tyrosinase-
negative oculocutaneous albinism, will never develop any melanin pigment in the skin, hair, and
eyes throughout his or her life.
 
20
 
 Some inborn errors in metabolism are relatively harmless, e.g.,
albinism or alkaptonuria, but others must be detected early if the defect is to be circumvented. This
is the case of phenylketonuria, where the enzyme phenylalanine 4-monooxygenase (enzyme that
converts phenylalanine into tyrosine) is missing. Phenylketonuria results in the accumulation of
phenylalanine, which may cause mental retardation. Patients with phenylalanine 4-monooxygenase
deficiency must follow a phenylalanine-free diet in order to avoid the accumulation of deleterious
effects. Phenylalanine is, however, an amino acid essential to maintain growth and protein turnover,
and thus it must be supplied in a minimal amount required to maintain normal metabolism. Such
a dietary scheme is normally carried out
 
11,16
 
 by lowering the amount of protein consumed, but this
may cause a deficiency in other essential amino acids. A possible alternative to this therapy is to
replace the missing enzyme. It may be difficult to find, however, an enzyme with the same function
from a human source since the direct administration of enzymes from other sources into the body
would cause an adverse immunological response. A possible approach to circumvent this problem
 
TABLE 17.1
Some Examples of Inborn Errors and Disorders Associated with Enzyme Deficiencies
 
Inborn Error/Disorder Enzyme Deficiency Frequency (%) Ref.
 
Gaucher disease Glucocerebrosidase 0.003–0.002 11, 13–15
Acatalasemia Catalase 0.004–0.004 11
Hypophosphatasia Alkaline phosphatase
 
ª 0.001 11, 15
Glycogen storage disease type Ia Glucose 6-phosphatase 0.001 11, 15
Alkaptonuria Homogentisate 1,2-dioxygenase 0.0001–0.001 11
Phenylketonuria Phenylalanine 4-monooxygenase 0.005–0.01 11, 15, 16
Fructosuria Fructokinase 0.0008 11
Pentosuria L-Xylulose reductase 0.04 in Ashkenazi Jews 11
Tay-Sachs
 
b-N
 
-acetyl-D-hexosaminidase 0.0003 11, 13–15
Infantile neuronal ceroid 
lipofuscinosis (INCL)
Palmitoyl protein thioesterase 1
(PPT1)
 
ª 0.013 live births 17, 18
Cystic fibrosis Cystic fibrosis transmembrane 
conductance regulator
0.03–0.05 Caucasians, rare
in other ethnic groups
11
Albinism Tyrosinase 0.02 schoolchildren in 
Zimbabwe
16, 19, 20
Glucose-6-phosphate dehydrogenase
deficiency
Glucose-6-phosphate 
dehydrogenase
0.5–26 11, 21, 22
Neonatal jaundice Biotinidase 0.0025 23, 24
Prolidase deficiency (PD) Prolidase — 25
Pompe’s disease
 
a-glucosidase — 13, 14
Severe combined immunodeficiency 
(SCID)
Adenosine deaminase — 12, 15, 26
Xanthinuria Xanthinine oxidase — 12
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involves the isolation of the enzyme within a microcapsule, fiber, or gel, which will protect the
enzyme from proteolysis and avoid the undesirable immunological response (please see Section
17.3.2.2 of this chapter).
The pharmacological properties of enzymes have been employed to replace enzymes that are
missing or defective as a consequence of an inherited disease or malfunction of an organ where
they are normally synthesized or to accomplish a certain biological effect that is dependent on the
catalytic activity of the enzyme. Therefore, depending on the treatment, the administration of
enzymes as therapeutic agents can be subdivided into two categories
 
9,11
 
: (1) the topical application
of an enzyme as an extracellular agent and (2) the intracellular applications of enzymes to treat
metabolic deficiency and related disease. The main areas where enzyme therapy has been applied
are the degradation of necrotic tissue by the use of proteolytic enzymes, removal of toxic compounds
from the blood, treatment of genetic deficiency diseases and cancer, and treatment of pancreatic
insufficiency.
 
11
 
 In Table 17.2 are given some examples of areas where enzyme therapy may be used.
Enzymes may be administered either intra- or extracorporeally, depending on the objective. If
the enzyme is to be used for the removal or transformation of a substance present in the blood
(e.g., toxic metabolite or a blood clot), then it is only necessary for the enzyme to be present in
the blood and not necessary for the enzyme to enter the intracellular compartments. This type of
application may be either intra- or extracorporeal using a bypass as in kidney dialysis. These systems
 
TABLE 17.2
Enzymes with Therapeutic Importance for Medical Applications
 
Enzyme Typical Applications Ref.
 
Lysozyme Recommended in treatment of certain ulcers, measles, multiple sclerosis, some 
skin diseases, and postoperative infections (antibacterial agent)
27–29
Urease Biosensor and artificial kidneys 30–32
Catalase Treatment of acatalasemia and removal of hydrogen peroxide in human cells 33–35
Glucose-6-phosphate 
dehydrogenase
Treatment of jaundice 36–38
Collagenase Skin ulcers 11
Glucose oxidase Glucose test in blood and urine 39, 40
Asparaginase Anticancer agent (leukemia) 41–43
 
a-amylase, protease, 
lipase
Digestive aids 44
Chymotrypsin and pepsin Catalyzes the hydrolysis of peptide bonds of proteins in the small intestine 45
Trypsin Anti-inflammatory agent, wound cleanser 44, 46, 47
Streptokinase Anti-inflammatory agent, dissolution of blood clots in myocardial infarction 45
Hyaluronidase Hydrolyses polyhyaluronic acid, a relatively impermeable polymer found 
between human cells; administered to increase diffusion of coinjected 
compounds, e.g., antibiotics, adrenaline, heparin, and local anesthetic in 
surgery and dentistry. 
48–51
Heparinase Removal of heparin after surgery. Production of heparin oligosaccharides 
(wound healing and tumor netastasis properties).
52, 53
Urokinase Prevention and removal of blood clots 54–56
Streptodornase Anti-inflammatory agent 57
Tissue plasminogen 
activator (TPA)
Dissolution of blood clots 58
Tyrosinase Enzyme essential for the production of cellular pigments 20, 59, 60
Bilirubin oxidase Treatment of neonatal jaundice 61
Penicillinase Removal of allergenic form of penicillin from allergic individuals 16
Alkaline phosphatase Treatment of hypophosphatasia 15
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will be described in more detail in Section 17.3.2.3 of this chapter. For intracellular therapy, it is
necessary for the enzyme to be taken up by the appropriate target cells.
Although the attempts made with enzyme therapy in clinical trials have so far had limited success,
it is reasonable to assume that the delivery of enzymes (discussed in Section 17.3.2.2 of this chapter)
would constitute a feasible approach for the treatment of certain diseases in the near future.
 
17.3 ENZYME IMMOBILIZATION TECHNOLOGY
 
The term 
 
immobilized enzyme
 
 was adopted in 1971
 
62
 
 at the first Enzyme Engineering Conference.
It describes enzymes physically confined at or localized in a certain region of space with retention
of catalytic activity and which can be used repeatedly and continuously.
 
63
 
 The immobilization of
biocatalysts (not only enzymes but also other bioactive molecules such as growth factors and
hormones, cellular organelles, microbial cells, and plant and animal cells) is attracting worldwide
attention in biotechnology applications. In general, immobilized biocatalysts are more stable and
easier to handle compared with their free counterparts.
 
64
 
 At present, applications of immobilized
biocatalysts include the production of useful compounds by stereospecific or regiospecific biocon-
version, the production of energy by biological processes, the selective treatment of specific
pollutants to solve environmental problems, continuous analyses of compounds with a high sensi-
tivity and specificity, and medical uses such as new types of drugs for enzyme therapy or artificial
organs.
 
14
 
 Immobilized enzymes are already being used in medical applications for clinical diagnosis
and also for intra- and extracorporeal enzyme therapy.
 
62
 
 Applications in clinical analysis are mainly
related to biosensors, which have been used to detect the presence of various organic compounds
for many years. For example, glucose oxidase and catalase have been used to measure blood glucose
concentration, and cholesterol oxidase and cholesterol esterase to determine cholesterol levels.
 
31
 
 In
addition, enzymes can be immobilized on different prosthetic devices or used extracorporeally (e.g.,
artificial heart, artificial lung, artificial kidney, equipment for hemodialysis and specific blood
purification) as surface modifiers in order to increase the biocompatibility of these devices and to
prevent blood clotting.
 
9
17.3.1 M
 
ETHODS 
 
FOR I
 
MMOBILIZING E
 
NZYMES 
 
IN P
 
OLYMERIC C
 
ARRIERS 
 
Various methods have been developed
 
10,65
 
 for the immobilization of biocatalysts, which are being
used extensively today. A wide range of support materials has also been employed for enzyme
immobilization. The support type can be classified according to their chemical composition, such
as organic or inorganic supports, and the former can be further classified into natural or synthetic
matrices.
 
66
 
 Immobilization techniques can be divided into different categories: physical,
 
67
 
 chemi-
cal,
 
68
 
 enzymatic,
 
69
 
 and genetic engineering methods.
 
53
 
17.3.1.1 Adsorption
 
The adsorption of an enzyme onto a support or film material is the simplest method of obtaining
an immobilized enzyme. Basically, the enzyme is attached to the support material by noncovalent
linkages and does not require any preactivation step of the support. The interactions formed between
the enzyme and the support material will be dependent on the existing surface chemistry of the
support and on the type of amino acids exposed at the surface of the enzyme molecule. Enzyme
immobilization by adsorption involves, normally, weak interactions between the support and the
enzyme such as ionic or hydrophobic interactions, hydrogen bonding, and van der Waals forces
(see Figure 17.1).
 
70,71
 
Most of the support materials available have sufficient surface-charge properties suitable for
immobilization by adsorption. They include inorganic carriers
 
62
 
 (ceramic, alumina, activated carbon,
kaolinite, bentonite, porous glass), organic synthetic carriers
 
72
 
 (nylon, polystyrene), and natural
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organic carriers
 
1
 
 (chitosan, dextran, gelatin, cellulose, starch). The method consists of simply mixing
an aqueous solution of enzyme with the support material for a period of time, after which the
excess enzyme is washed away from the immobilized enzyme on the support. The procedure
requires strict control of the pH and ionic strength, because these can alter the charges of the
enzyme and the support and therefore affect the level of adsorption. A simple shift in pH can cancel
ionic interactions and promote the release of the enzyme from the support. The main advantages
of adsorption are the method simplicity, the little effect on the conformation/activity of the biocat-
alyst, and the possibility of regenerating inactive enzyme by addition of fresh enzyme. The main
disadvantage is the desorption of the biocatalyst from the support due to the weak interactions
established. The enzyme desorption can easily occur by changes in the environment medium such
as pH, temperature, solvent, and ionic strength or in the case of extended reactions.
 
73
 
17.3.1.2 Ionic Binding
 
Immobilization via ionic binding is based, mainly, on ionic binding of enzyme molecules or active
molecule to solid supports containing ionic charges. In this method, the amount of enzyme bound
to the carrier and the activity after immobilization depends on the nature of the carrier. Figure 17.2
shows how the enzyme is bound to the carrier. In some cases, physical adsorption may also take
place. The main difference between ionic binding and physical adsorption is the strength of the
interaction, which is much stronger for ionic binding, although less strong than covalent binding.
The preparation of immobilized enzymes using ionic binding is based on the same procedure as
described for physical adsorption.
 
74,75
 
 The ionic nature of the binding forces between the enzyme
and the support also depends on pH variations, support charge, enzyme concentrations, and tem-
perature. The supports used for ionic binding may be based on polysaccharide derivatives
 
64
 
 (e.g.,
diethylaminoethylcellulose, dextran, chitosan, carboxymethylcellulose), synthetic polymers
 
10
 
 (e.g.,
 
FIGURE 17.1
 
Biocatalysts bound to a carrier by adsorption.
 
FIGURE 17.2
 
Biocatalysts bound to a carrier by ionic binding. 
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polystyrene derivatives, polyethylene vinylalcohol), and inorganic materials
 
62
 
 (e.g., ambertite, alu-
mina, silicates, bentonite, sepiolite, silica gel, etc.). The immobilization by ionic binding has the
advantage that changes in the enzyme conformation only occur in a small extent, resulting in
immobilized enzymes with high enzymatic activities. The main disadvantage is the possible inter-
ference of other ions, and special attention should be paid in maintaining the correct ionic strength
and pH conditions in order to prevent their easy detachment.
 
10
 
17.3.1.3 Covalent Binding by Chemical Coupling
 
The covalent binding
 
 
 
method is based on the binding of enzymes, or other active molecules, to a
support or matrix by means of covalent bonds.
 
10
 
 The bond is normally formed between a functional
group present on the support surface and amino acid residues on the surface of the enzyme. Those
which are most often involved in covalent binding are
 
65
 
 the amino (NH
 
2
 
) group of lysine or arginine,
carboxyl (CO
 
2
 
H) group of aspartic acid or glutamic acid, hydroxyl (OH) group of serine or threonine,
and sulphydryl (SH) group of cysteine.
 
76,77
 
 There are many reaction procedures for joining an enzyme
to a material with a covalent bond (diazotation, amino bond, Schiff’s base formation, amidation
reactions, thiol-disulfide, peptide bond, and alkylation reactions). The connection between the
support and the biocatalyst can be achieved either by direct linkage between the components or via
an intercalated link of different length, the so-called spacer or harm. The advantage of using a spacer
molecule is that it gives a greater degree of mobility to the coupled biocatalysts so that its activity
can, under certain circumstances, be higher than if it is bound directly to the support (see Figure
17.3). It is important to choose a method that will not involve the reaction with the amino acids
present in the active site, since
 
 
 
this could inactivate the enzyme. Basically, two steps are involved
in the covalent binding of enzymes to a support material. First, functional groups on the support
material are activated by specific reagents (e.g., cyanogen bromide, carbodiimide, aminoalkylethox-
ysilane, isothiocyanate, and epichlorohydrin, etc.). A large range of support materials is available
for covalent binding, and this extensive range reflects the fact that no ideal matrix exists. Therefore,
the advantages and disadvantages of a given matrix must be taken into account when considering
the appropriate procedure for a given enzyme immobilization. Immobilization of enzymes through
covalent attachment has also been demonstrated
 
73
 
 to induce higher resistance to temperature, dena-
turants, and organic solvents in several cases. The extent of these improvements may depend on
other conditions of the system, e.g., the nature of the enzyme, type of support, and the method of
immobilization. Many factors may influence the selection of the support, and some of the more
important are its cost and availability, the binding capacity (amount of enzyme bound per given
weight of matrix), hydrophilicity (the ability to incorporate water into the matrix and stability of
matrix), structural rigidity, and durability during applications. Natural polymers, which are very
hydrophilic, are popular support materials for enzyme immobilization since the residues in these
 
FIGURE 17.3
 
Covalent bond between the biocatalysts and a carrier with (a) and without spacer (b).
 (b) (a) 
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polymers contain hydroxyl groups, which are ideal functional groups for participating in covalent
bonds. A frequently encountered disadvantage of immobilization by covalent binding is that it places
great stress on the enzyme. The necessary harshness of the immobilization procedure nearly always
leads to considerable changes in conformation and a resultant loss of catalytic activity.
 
72,78,79
 
17.3.1.4 Crosslinking
 
The crosslinking method is based on the formation of covalent bonds between the enzyme or active
molecules, by means of bi- or multifunctional reagents.
 
80,81
 
 The individual biocatalytic units
(enzymes, organelles, whole cells) are joined to one another with the help of bi- or multifunctional
reagents (e.g., glutardialdehyde, glutaraldehyde, glyoxal, diisocyanates, hexamethylene diisocyan-
ate, toluene diisocyanate, etc.). Enzyme crosslinking involves normally the amino groups of the
lysine but, in occasional cases, the sulfhydryl groups of cysteine, phenolic OH groups of tyrosine,
or the imidazol group of histidine can also be used for binding. Figure 17.4 shows how the
biocatalysts can be linked by a simple crosslinking process (Figure 17.4a) and also by co-crosslink-
ing, in which inert molecules are incorporated in the high-polymer network in order to improve
the mechanical and enzymatic immobilized preparation (Figure 17.4b).
The advantages and disadvantages of a given matrix must be taken into account when consid-
ering the appropriate procedure for a given enzyme immobilization. One advantage is the simplicity
of the process. The main disadvantages are the fragility of the particles produced in some cases
and diffusion limitations. Since crosslinking and co-crosslinking usually involve covalent bonds,
immobilized biocatalysts in this way frequently undergo changes in the conformation with a
resultant loss of activity. The isomerization of glucose process is a very important example of the
industrial application using biocatalysts crosslinked with glutaraldehyde. Some of the immobilized
preparations used in these large-scale processes are produced simply by glutaraldehyde treatment
of bacterial cell masses that have formed fine particles.
 
10
 
17.3.1.5 Entrapment and Encapsulation
 
The entrapment method for immobilization consists of the physical trapping of the active compo-
nents into a film, gel, fiber, coating, or microencapsulation
 
73
 
 (see Figure 17.5). This method can
be achieved by mixing an enzyme or active molecule with a polymer and then crosslinking the
polymer to form a lattice structure that traps the enzyme. Microencapsulated enzymes are formed
by enclosing enzymes solution within spherical semipermeable polymer membranes with con-
trolled porosity.
While the encapsulation of dyes, drugs, and other chemicals has been known for some time,
it was not until the mid-1960s that such a method was first applied to enzymes. Since that first
report, a number of other enzymes have been successfully immobilized via microencapsulation,
 
FIGURE 17.4
 
Biocatalysts immobilized by means of crosslinking (a) and co-crosslinking with inert molecules
incorporated (b).
 
 
 
 
 
 
 
 
 
 
 
(a) (b) 
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using a number of different materials and methods to prepare the microcapsules. The advantages
of this immobilization method are the extremely large surface area between the substrate and the
enzyme, within a relatively small volume, and the real possibility of simultaneous immobilization.
The major disadvantages of this method include the occasional inactivation of enzyme during
microencapsulation and the high enzyme concentration required. In addition, to retain the enzyme,
the pore size needs to be very low and these systems tend to be very diffusion limited.
 
72
 
17.3.1.6 Protein Fusion to Affinity Ligands and Enzymatic Conjugation
 
As described before, there are many methods for protein immobilization, but some of them require
chemical modification of the matrix, which may result in material degradation, especially when
biodegradable polymers are used. In addition, these modifications, necessary to attach the enzyme
to the matrix, often result in the loss of enzyme activity as well as the inclusion of toxic organic
compounds, which have to be removed before the system can be used in biomedical applications.
In this type of application, the efficacy of immobilized biomolecules for stimulating specific cell
responses (e.g., proliferation or differentiation) depends on the mode by which these modulators
are presented to the target cells. In these cases, it is important to ensure the correct orientation and
full bioactivity of the molecules when they are immobilized. Covalent binding by chemical coupling,
again, might hinder ligand–receptor interaction or prevent receptor dimerization and capping on
target cells.
In nature, there are certain protein molecules, such as lectins,
 
14,82
 
 avidin,
 
83
 
 immunoglobulin G
(IgG) binding domains of protein G and protein A,
 
84,85
 
 and carbohydrate binding modules
 
86,87
 
(present in many polysaccharide-degrading enzymes), that bind with high affinity and specifically
to certain molecules or solid surfaces. These binding domains may be used as affinity tags for
immobilizing proteins to affinity adsorbents. In this technique, DNA encoding a polypeptide affinity
tag is fused to the gene of interest, and the expression of the gene results in a fusion protein. Such
a fusion protein could be immobilized by the specific binding of the affinity tag to an affinity
adsorbent (Figure 17.6a). With this method, the conformational changes in the protein upon
immobilization are minimal, and the immobilized biomolecule could retain high activity. In addi-
tion, since fusion proteins are specifically immobilized on the support materials, these methods
normally allow the immobilization of high densities of ligands and can also simplify the immobi-
lization procedure.
The use of genetic engineering techniques to construct chimeric proteins, containing a functional
domain displaying bioactivity together with an affinity domain, has proven to be a very useful
approach for immobilizing biomolecules on solid materials. Several proteins, including
 
FIGURE 17.5
 
Enzyme encapsulation in a matrix (a), fiber (b), or capsule (c).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
(a) (c) 
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enzymes,
 
53,88,89
 
 antibodies,
 
90,91
 
 cytokines,
 
92
 
 and streptavidin,
 
93
 
 have been immobilized on the surface
of cellulosic matrices by fusing genetically these proteins to cellulose-binding domains.
By using protein fusion techniques, bifunctional proteins can be prepared without changing
their activity and binding properties.
 
53,87,89
 
 This approach has found various applications in biotech-
nology, diagnostics, and medicine for the purification and immobilization of biologically active
proteins. It can be used, for instance, to promote the attachment of several mammalian cells to
different surfaces by fusing a variety of peptides, growth factors, and cytokines to a specific binding
domain, and this might be useful for the activation and growth of progenitor cells in culture.
The binding affinity between streptavidin and biotin is among the strongest noncovalent bonds
known to exist (
 
K
 
D
 
 = 10
 
–15
 
 
 
M
 
).
 
83
 
 Therefore, the high affinity coupling of the biotin–avidin system
has been used to immobilize different biomolecules on the surface of biomaterials and biosen-
sors.
 
94,95
 
 It consists of using avidin as a bridge between the biotinylated surface and biotinylated
short ligand molecules.
The immobilization of biomolecules on protein matrices may also be achieved via an enzymatic
reaction catalyzed by transglutaminase (TG) enzyme. TG catalyzes the acyl transfer reaction
between the 
 
g
 
-carboximine group of a peptide-bound glutaminyl residue and a primary amino group
of various protein substrates. The result of this reaction is the formation of an irreversible
crosslinked, insoluble supramolecular structure.
 
96
 
 In addition, TG can be used to bind glutamine-
 
FIGURE 17.6
 
Enzyme immobilization to solid matrices via protein fusion to an affinity ligand (a) and
enzymatic conjugation catalyzed by transglutaminase (b).
 
 A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Solid Support
ffinity tag
Enzyme
Linker
(a)
Protein matr ix
TG
T G substr ate
Enzyme or  growth factor
Peptide linker
(b)
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containing peptides or polypeptides to NH
 
2
 
 surfaces,
 
69
 
 and this methodology is schematically
represented in Figure 17.6b. This approach was used by Sakiyama et al.
 
97,98
 
 to incorporate heparin-
binding peptides and to design a growth factor delivery system. In the latter work, they developed
a growth factor fusion protein, containing a bi-domain peptide consisting of a 
 
b
 
-nerve growth factor
(
 
b
 
-NGF) and an exogenous factor XIIIa (substrate for enzymatic crosslinking). The fusion protein
was covalently immobilized within a three-dimensional cell in-growth matrix based on fibrin using
the transglutaminase activity of factor XIIIa.
 
17.3.2 E
 
NZYME I
 
MMOBILIZATION 
 
IN B
 
IOMEDICAL A
 
PPLICATIONS 
 
Biomaterials can be combined with biomolecules, such as enzymes and growth factors, to yield
biologically functional systems. There is a wide and diverse range of materials and methods
available for enzyme immobilization on or within the biomaterial. The methods for immobilizing
enzymes and other biomolecules are the same as described in Section 17.3.1 of this chapter, but
the choice of the method depends largely on the final application. Furthermore, the criteria for
selecting the immobilization methods should also take into account that the immobilized enzyme
should retain an acceptable level of activity over a certain period of time in terms of economic or
clinical aspects.
The methods used for the administration of immobilized enzymes may be divided into two
principal groups
 
9
 
: immobilized enzymes that are intended for prolonged circulation and enzymes
that must be necessarily present in different tissues and organs of the body. In the second case, the
immobilized enzyme is intended for local deposition during the treatment of discrete lesions (e.g.,
thrombi, tumors, atherosclerotic injuries) or of the individual organs.
 
9
 
Table 17.3 describes some examples of immobilized enzymes in various biomaterial supports
for different biomedical applications.
 
17.3.2.1 Biologically Functional Surfaces
 
Biomaterials, especially when used in tissue engineering applications, must have the capacity to
induce tissue regeneration/repair in order to achieve a more rapid recovery of the defect. At present,
the existing scaffolds are not satisfactory in achieving rapid and full recovery of the defect. The
attachment of cells to biomaterials, and their subsequent spreading, are mediated by extracellular
matrix (ECM) glycoproteins such as fibronectin, collagen, etc. ECM glycoproteins contain short
sequences with cell attachment properties, which interact with the integrin family of cell surface
receptors. The peptide sequence Arg-Gly-Asp (RGD) has been identified as being capable of
interacting with cell surface receptors. Thus, the immobilization of biologically active molecules
on the surface of biomaterials for presenting effectors to target cells or to induce a particular effect
is of great interest, since the immobilization of active agents presents the advantage of providing
a continuous and localized stimulus for cell proliferation. Unlike nonimmobilized active agents,
which are often consumed by cells, immobilized biomolecules remain bound to a substrate that is
not consumed by cells and thus remain available to stimulate growth of additional cells. This is
particularly useful in perfusion cultures in which growth medium is continuously added and
removed to allow long-term cell proliferation.
Biodegradable polymers have been used as scaffolding materials for various tissue engineering
applications because they can provide the support on which cells and tissues can adhere, but they
can also guide and regulate the proliferation and activities of the adhered cells. However, the
intrinsic hydrophobic property of some of these polymers
 
108
 
 restricts their applications as cell
colonizing materials. Many
 
 
 
methods have been used to modify the properties of polymer surface,
such as plasma treatment-induced grafting polymerization, ozone oxidation, and immobilization of
enzymes, and special biologically active agents have been used to introduce reactive groups onto
polymeric surfaces.
 
109
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Various strategies have been developed to incorporate bioactive agents on the surface of
biomaterials for controlling cell and tissue responses. The immobilization process can be involved,
enriching surfaces for enhancing the cellular adhesion. Biomolecules such as enzymes, antibodies,
antigens, peptides, or drugs have been immobilized on or within polymeric systems. An example
of an adhesive protein is fibronectin, which is able to promote cellular adhesion through binding
to integrin receptors, and this interaction has also been shown to play a role in cell growth,
differentiation, and overall regulation of cell function.
 
77,110
 
 Hern and Hubbell
 
111
 
 showed that the
incorporation of the adhesion peptide RGD into a nonadhesive hydrogel proved to be useful for
tissue resurfacing. There are numerous other adhesion peptides for targeting particularly desirable
cell types and to modulate biological responses.
Urokinase has been widely used for the clinical treatment of thrombogenetic disease and
hemorrhoidal disease. Artificial organ materials, on which urokinase was immobilized for its
 
TABLE 17.3
Examples of Immobilized Enzymes in Various Biomaterials for Different Biomedical 
Applications
 
Enzyme Biomaterial (Carrier)
Immobilization
Method Application Ref.
 
Alkaline phosphatase pHEMA
 
a
 
Glassy carbon
Entrapment
Protein fusion to 
affinity tag
Induction of bone and cartilage 
mineralization
Biosensor/enzyme-linked 
immunoassays
99
95
 
a-amylase pHEMA
 
a
 
Starch polymeric blend
Covalent binding
Encapsulation
Fixed-bed reactor
Tailor the degradation rate of starch-
based biomaterials
100
101
 
b-galactosidase Gelatin Encapsulation Not specified 102
Glucose oxidase Proteins Enzymatic 
conjugation
Biosensor 69
 
a-chymotrypsin Cellophane Plasma modification/
covalent binding
Not specified 103
Acetylcholinesterase
Choline oxidase
pHEMA
 
a
 
Entrapment
Covalent binding
Ionic interactions
Biosensor 104
Papain Polyethylene
Glass surfaces
Plasma modification
Covalent binding
Not specified 105
Lysozyme Gelatin and succinylated
gelatin
Poly(ethylene glycol)–
poly(aspartic acid)
copolymer
Adsorption
Ionic interactions
Entrapment/ionic 
binding
Reduction of prosthetic valve 
endocarditis
Delivery of lysozyme as a lytic 
enzyme
106
28
Heparinase Sepharose Covalent binding Bioreactor for extracorporeal 
elimination of heparin from blood
52
Phospholipase A
 
2
 
Agarose Not mentioned Bioreactor for treatment of 
hypercholesterolemia (reduce 
plasma cholesterol)
107
Bilirubin oxidase Agarose Covalent binding Bioreactor for removal of bilirubin 
from blood
61
Prolidase PLGA
 
b
 
 microspheres Encapsulation Enzyme replacement therapy 25
 
a
 
Poly(2-hydroxy ethyl methacrylate).
 
b
 
Poly(
 
D,L
 
-lactide-co-glycolide).
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fibrinolytic activity, have been developed for blood-compatible materials. For example, Liu et al.
 
55
 
immobilized urokinase by encapsulation in poly(2-hydroxyethyl methacrylate) and König
 
 
 
et al.
 
56
 
introduced urokinase on the surface of the polytetrafluoroethylene using plasma modification
technique by covalent bond. Another example of immobilized urokinase application was reported
by Kato and coworkers,
 
54
 
 who had used urokinase immobilized in a Teflon catheter for treatment
of thrombosis.
Most of the studies found in the literature, regarding the surface functionalization
 
 
 
of biomaterials
with biological molecules, include the incorporation of adhesion and differentiation factors. The
same approach may be used to incorporate specific enzymes able to regulate a number of cell
functions. For instance, it is known that mitogen activated protein (MAP) kinase, upon activation
by dual phosphorylation at threonine and tyrosine residues, is able to activate downstream targets
that have been implicated in controlling gene expression, cell differentiation, and proliferation.
 
112
 
This enzyme may be immobilized on the surface of biomaterials to control cell response, but other
possibilities using different enzymes remain unexplored.
 
17.3.2.2 Enzyme Delivery
 
Although purified enzymes are now available for some enzyme deficiency diseases (see Table 17.1),
there are many problems in delivering the enzyme to the required site under such conditions that
it will remain stable and active for a reasonable time. Normally, quite large amounts of enzyme
are necessary with high level of purity and in a nonimmunogenic form.
 
9,14,113,114
 
 In addition, many
enzymes when administered are inactivated or degraded fairly rapidly. The delivery of therapeutic
molecules requires, therefore, efficient strategies to have a precise control on their release profile
according to specific locations. It might be possible to control the release of such molecules by
creating delivery systems sensitive to changes in pH, temperature, or salt concentration or to the
feedback provided by cells. The concept of enzyme-activated drugs in therapy is scientifically, as
well as clinically, attractive, as it allows the chemist and enzymologist full intellectual rein in
designing interlinked systems.
 
114
 
 As therapeutic drugs, enzymes possess several attributes such as
high specificity toward substrate, high solubility for preparing liquid formulations, and optimum
activity under physiological conditions.
 
115
 
 The administration of enzymes, in cases of enzyme
deficiency and inborn errors of metabolism and in the treatment of certain types of cancer, appears
to offer a successful form of therapy. Cancer therapy based on the delivery of enzymes to tumor
sites has advanced in several directions since antibody-directed enzyme/prodrug therapy was first
described.
 
116
 
 Nanospheres, nanocapsules, liposomes, micelles, and other nanoparticulates are fre-
quently referred to as carriers for delivery of therapeutic and diagnostics agents.
 
113
 
Asparagine is an essential amino acid for certain types of leukemias that lack asparagines
synthetase activity. The activity of 
 
L
 
-asparaginase is to degrade asparagine into aspartate and
ammonia. Therefore, asparaginase has been of interest to biochemists and clinicians as a possible
cancer therapeutic agent. Some success has been achieved in administering asparaginase in capsules
made of nylon and polyurea to mice and rats. Although asparaginase has been found to be effective
in the treatment of some patients,
 
117
 
 it may have several serious side effects.
 
41
 
 Relatively high
concentrations of the enzyme are needed for it to be clinically effective. These levels cause a wide
range of toxic effects on several organs including the liver, pancreas, kidneys, and brain. The enzyme
may also be recognized as foreign by the body and potentially severe immunogenic responses will
be stimulated, resulting in hypersensitivity reactions. To overcome these problems, immobilized
enzyme derivatives have been prepared on various supports for extracorporeal treatment (please
see Section 17.3.2.3 of this chapter).
Enzymes may be also used in cancer therapy as prodrug activators. This therapy consists
basically in using a drug that has been chemically modified so that it remains inactive until
specifically activated by an enzyme at the target site.
 
11
 
1936_C017.fm  Page 313  Saturday, October 2, 2004  12:50 PM
 314
 
Biodegradable Systems in Tissue Engineering and Regenerative Medicine
 
Another example of an anticancer enzyme is hyaluronidase.
 
50
 
 Hyaluronidase is a globular
enzyme of endoglycosidase action, which can depolymerize hyaluronic acid in the organism,
decreasing its viscosity and increasing tissue permeability. Hyaluronidase has been utilized exten-
sively as an adjunct in anticancer chemotherapy regimens, suggesting that hyaluronidase has
intrinsic anticancer properties against tumor growth.
 
51
 
 
 
In vitro
 
 studies in tissue culture with tumor
spheroids and 
 
in vivo
 
 tests using animal models demonstrated the beneficial effect of hyaluronidase
for the penetration of drugs into tumor tissue. Later, in a prospective clinical trial, hyaluronidase
significantly improved the outcomes of patients with bladder carcinoma if the enzyme was admin-
istrated topically together with mitomycin C.
 
49,50
 
 Hyaluronidase is also used for local application
(subcutaneous injections) during treatment of joint disease, in dermatology, and in ophthalmology.
 
48
 
Hyaluronidase had been used in ophthalmology with the aim of formation of a thinner scar and to
prevent necrosis after paravataes with zytostatics.
Trypsin has also been used to remove dead tissue from wounds, burns, and ulcers to speed the
growth of new tissue and skin grafts, as well as to inhibit the growth of some contaminant organisms.
The inappropriate activation of trypsinogen within the pancreas leads to development of pancre-
atitis.
 
47
 
 Once trypsin is activated, it is capable of activating many other digestive pro-enzymes.
These activated pancreatic enzymes further enhance the auto-digestion of the pancreas. Many
materials, such as nylon, polysulfone, glycidyl methacrylate, chitosan, cellulose, and cellulose
derivatives, have been used for trypsin immobilization.
 
44,46,47
 
Enzyme therapy has also been tested for pancreatic insufficiency and cystic fibrosis. Pancreatic
insufficiency can be alleviated by administrating orally enteric-coated microspheres containing
lipase, amylase, and proteases. A special polymer coating protects the enzymes at low pH, such as
in the stomach, and then releases them in the intestine at physiological pH.
 
11,14
 
Lysozyme is a good example of an enzyme that catalyzes chemical reactions in the cell.
Lysozyme acts to kill bacteria by cleaving the covalent bond between the alternating polysaccharides
that compose peptidoglycan in bacterial cell walls.
 
27
 
 The human salivary defense proteins and
lysozyme are known to exert a wide antimicrobial activity against a number of bacterial, viral, and
fungal pathogens 
 
in vitro
 
. Therefore, these proteins, alone or in combinations, have been incorpo-
rated as preservatives in foods and pharmaceuticals as well as in oral health care products to restore
saliva’s own antimicrobial capacity in patients with dry mouth. These antimicrobials used in oral
health care products, such as dentifrices, mouth rinses, moisturizing gels, and chewing gums, have
been purified from bovine colostrum. Other studies had been reported with lysozyme bound to
chitosan, silica gel by means of physical adsorption, crosslinking to a polystyrene divinylbenzene
matrix by the formation of ionic bindings, and by covalent attachment to nonporous glass beads.
 
29
 
Harada and Kataoka
 
28
 
 described lysozyme immobilized into poly(ethylene glycol)–poly(aspartic
acid) micelle. Lysozyme was selected as a model protein to incorporate into the micelle because
it has a high isoelectric point (pI = 11), is positively charged over a wide range of pH, and has
practical usage in drug delivery application as a lytic enzyme. Chen and Chen
 
118
 
 prepared immo-
bilized lysozyme by carbodiimide
 
 
 
method to form amide bonds with an enteric coating polymer
(hydroxypropyl methyl-cellulose acetate succinate [AS-L]) as the carrier, which shows reversibly
soluble-insoluble characteristics with pH changes.
The glucose-6-phosphate dehydrogenase enzyme catalyzes the oxidation of glucose-6-phos-
phate to 6-phosphogluconate while concomitantly reducing the oxidized form of nicotinamide
adenine dinucleotide phosphate (NADP
 
+
 
) to nicotinamide adenine dinucleotide phosphate
(NADPH). NADPH, a required cofactor in many biosynthetic reactions, maintains glutathione in
its reduced form. Reduced glutathione acts as a scavenger for dangerous oxidative metabolites in
the cell. With the help of the enzyme glutathione peroxidase, reduced glutathione also converts
harmful hydrogen peroxide to water. Red blood cells rely heavily on glucose-6-phosphate dehy-
drogenase activity because it is the only source of NADPH that protects the cells against oxidative
stresses. People deficient in glucose-6-phosphate dehydrogenase are not prescribed, therefore,
with oxidative drugs because their red blood cells undergo rapid hemolysis under this stress.
 
36
 
 In
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Greece, glucose-6-phosphate dehydrogenase deficiency is the main cause of severe neonatal
jaundice. The deficiency of this enzyme affects all races; the highest prevalence is among persons
of African, Asian, or Mediterranean descent.
 
37
 
 Study of immobilized glucose-6-phosphate dehy-
drogenase has been reported. Kotorman et al
 
.
 
38
 
 immobilized glucose-6-phosphate dehydrogenase
from yeast on polyacrylamide beads possessing carboxylic functional groups activated by a water-
soluble carbodiimide. They verified highest operational stability of immobilized glucose-6-phos-
phate dehydrogenase.
In relation to the use of immobilized enzymes with therapeutic purposes, catalase is one of the
most interesting because it is employed to accelerate healing as well as to correct hereditary
deficiencies and, in combination with hydrogen peroxide, as an antiseptic against anaerobes.
 
33,34
 
The catalase enzyme has the ability to decompose hydrogen peroxide into oxygen and water, playing
a central role in controlling the hydrogen peroxide concentration in human cells. More than 98%
of blood catalase is localized in erythtocytes.
 
119
 
 These cells, with their high catalase level, provide
a general protection against the toxic concentration of this small hydrogen peroxide molecule. The
deficiency of catalase could cause acatalasemia.
 
35,119
 
 Several methods have been developed for the
immobilization of catalase.
 
1,74,120
 
 Immobilization is often accompanied by changes in the enzymatic
activity, optimum pH, affinity to the substrate, and stability. The extent of these changes depends
on the enzyme, carrier support, and the immobilization conditions.
 
121
 
 The shift in the optimum pH,
from acidic or alkaline to neutral pHs, may be useful for biomedical applications since it will allow
the use of some enzymes (more active at low or high pHs) under more physiological conditions.
The approach developed by Sakiyama-Elbert et al.,
 
98
 
 consisting in a cell-triggered growth factor
delivery system, may also be used for the release of other important therapeutic molecules.
17.3.2.3 Bioreactors for Extracorporeal Enzyme Therapy
Extracorporeal shunts have been proposed72,122 for the treatment of several clinical conditions. The
most likely applications for enzymatic treatment are the removal of urea during kidney failure,
removal of toxins (e.g., paracetamol) during liver failure, or the reduction of key metabolites from
the circulation to treat cancer.
Urease is one of the most important enzymes in biomedical applications. Urease is an enzyme
that catalyzes the hydrolysis of urea to form ammonia and carbon dioxide. Urea is one of the main
metabolic end products, and the removal of its excess has been a major problem for patients suffering
from renal failure. Hence, its immobilization by entrapment has been investigated by many workers
for applications in biosensors and as artificial kidneys. The most attention has been given to the
development of enzyme reactors, where the urea would be removed and the dialysis fluid prepared
for further use.30,31 The use of this enzyme is often limited due to its high cost, availability in small
amounts, instability, and the limited possibility of feasible recovery of these biocatalysts from a
reaction mixture. Numerous synthetic and natural polymeric supports have been used for urease
immobilization, and their uses in medical and technical fields are well reported. The covalent bond
of urease in different supports has been reported in many studies. Some commonly used supports
are chitosan-poly(glycidil methacrylate), carboxymethylcellulose, polyurethane, sepharose-2B,
polyacrylamide, ion exchange resins, copolymers of polyglycidylmethacrylate, calcium alginate
beads, poly(vinyl alcohol) (PVA), hydroxyapatite, 2-dimethylaminoethylmethacrylate, poly(ethyl-
ene glycol dimethacrylate/2-hydroxy ethylene methacrylate) microbeads, poly(caprolactone)/starch,
and poly(orthoesters).32,109,123–125 
As mentioned before in Section 17.3.2.2 of this chapter, L-asparaginase has been used for
treating leukemias and disseminating cancers that require asparagines for growth, but this treatment
presents several serious side effects. To overcome these problems, immobilized enzyme derivatives
have been prepared on various supports for extracorporeal treatment. Blood can be passed over
the immobilized enzyme, thus depleting the asparagine supply needed by the cancer cells. The
enzyme does not come into direct contact with the organs to which it is toxic, and hypersensitivity
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reactions do not occur. With this type of treatment, however, the blood plasma must be first
separated from the cells to minimize cell damage and then passed through a separate column
containing the immobilized enzyme. This process requires that the blood remain outside the body
for relatively long periods of time, resulting in the denaturation and depletion of many plasma
proteins.41,42 Some techniques have been developed to minimize this problem, such as the use of
a porous hollow-fiber plasmapheresis device. With this system, the plasma can be separated from
the whole blood and contact with immobilized enzyme in one passage, thus minimizing its time
outside the body and then reducing the damage to the plasma proteins. Adsorption techniques have
been used to immobilize asparaginase onto hollow fibers after first coating the fibers with albumin
and then crosslinking the enzyme with glutaraldehyde.41,126 Maciel and Minim43 also reported that
the use of L-asparaginase covalently attached to nylon tubing may constitute a useful system to
be used in clinical applications.
Bilirubin oxidase is also an example of enzyme used in extracorporeal applications.61 All human
newborns accumulate bilirubin to levels greater that those in adults, and 20% accumulate enough
to stain their skin, resulting in jaundice. Bilirubin binds to cellular and mitochondrial membranes,
causing cell death in a variety of tissues. Clinically, bilirubin toxicity may lead to mental retardation,
cerebral palsy, deafness, seizures, or death. The most common treatments for jaundiced infants are
phototherapy and exchange transfusion. This technique presents serious problems such as hypogly-
cemia, hypocalcemia, acidosis, transmission of infectious, etc. Lavin et al.61 reported the use of a
highly specific enzyme to remove bilirubin from the bloodstream using a small reactor (extracor-
poreal circuit) containing bilirubin oxidase covalently immobilized in agarose beads. These research-
ers obtained good results for the removal of the bilirubin in humans and in genetically jaundiced rats.
Heparinase, an enzyme that degrades heparin into small polysaccharides, has also been immo-
bilized into an extracorporeal device (artificial kidney bioreactor) to eliminate the anticoagulant
properties of heparin (used to prevent clotting in the device) before the blood returns to the patient.52
17.3.2.4 Diagnostic Assays and Biosensors
Isolated or combined enzymes are being used in medicine as useful tools for clinical analysis.
About 50 different enzymes are used in different aspects of clinical diagnoses, and for most of
these, much higher levels of purity are required than for most industrial enzymes. Two of the major
enzymes used are peroxidase from horseradish and alkaline phosphatase from beef intestinal
mucosa, both being required for immunoassays. The enzymes may be used in test strips, ELISA,
biosensors, and autoanalyzers.11
The serum uric acid concentration is an important index for clinical diagnosis of gout, leukemia,
toxemia of pregnancy, and severe renal impairment.127 A number of enzymes are assayed in serum
and urine for diagnostic purposes; the more frequently used ones are discussed below.
Alkaline phosphatases (ALP) are a group of enzymes found primarily in the liver (isoenzyme
ALP-1) and bone (isoenzyme ALP-2). There are also small amounts produced by cells lining the
intestines (isoenzyme ALP-3), the placenta, and the kidney (in the proximal convoluted tubules).
What is measured in the blood is the total amount of alkaline phosphatase released from these
tissues into the blood. As the name implies, this enzyme works best at an alkaline pH (pH 10), and
thus the enzyme itself is inactive in the blood. Alkaline phosphatase acts by splitting off phosphorus
(an acidic mineral), creating an alkaline pH. The primary importance of measuring alkaline phos-
phatase is to check the possibility of bone or liver diseases.128
Another application of immobilized enzymes is the development of improved sensing devices.9
Because of their high specificity for given substances, enzymes and monoclonal antibodies are
particularly suitable for use as sensors.129 The membrane-covered electrode described by Clark in
1959 is the dominating sensor for the measurement of dissolved oxygen.130 Numerous modifications
of the original concept have been developed. For instance, biosensors using enzymes have been
used to detect the presence of various organic compounds, and recent developments have proven
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to be both rapid and highly selective. They have been used in important applications such as in
clinical laboratories, fermentation processes, and pollution monitoring.131 Most of them have used
a free or immobilized enzyme and an ion-sensitive electrode that measures indirectly (e.g., by
temperature or color changes produced by an enzymatic reaction) the presence of a product whose
formation is catalyzed by the enzyme. The biosensors usually have immobilized biological mole-
cules attached to the surface of a transducer that allows an electronic or optical signal to be converted
into an appropriate signal. This type of biosensor could be used to measure glucose, sucrose, lactose,
L-lactate, galactose, L-glutamate, L-glutamine, choline, ethanol, methanol, hydrogen peroxide,
starch, uric acid, etc., by using specific enzymes.31,127
Glucose oxidase is normally used to assay glucose concentration. Glucose sensors are the
biosensors that have attracted much interest in both research and applications fields. One particularly
important medical application of improved biosensors could be in the treatment of diabetic patients
for whom proper levels of insulin and glucose must be maintained. For instance, small implantable
devices for sampling blood to determine the levels of glucose and regulate the delivery of insulin
could be developed using this enzyme.39 A great variety of immobilization methods (e.g., encap-
sulation, entrapment) and transducers have been developed to construct the glucose sensors with
better performance and practicability since the work of Clark and Lyons in 1962.40 Several materials
have been used, such as polyethylene terephthalate (PET), polyacrylamide, N- isopolyacrylamide,
sol-gel, poly(2-hydroxyethyl methacrylate), alginate, artificial resins, glass, etc.31,78,132 
For example, Zhang and Cass133 have also immobilized alkaline phosphatase on a nanoporous
nickel-titanium film for sensor applications.
A number of other enzymes have been described with great potential for medical applications,
including carboxypeptidases, collagenase, fibrinolysin, pepsin,44 streptokinase,45 subtilisin, throm-
bin, tissue plasminogen activator, a-amylase, a-galactosidase, glucoamylase, lactase (-galactosi-
dase), pectinase, pancreatin, phospholipases, cholesterol esterase and other DNases, RNases, phos-
phatases, esterases, sulfatases, isomerases, glucose isomerase, superoxide dismutase, cholesterol
esterease, creatine kinase, and penicillin acylase.45,58,114,134–136
17.3.2.5 Advantages and Disadvantages of Immobilized Enzymes
The use of immobilized enzymes normally offers several advantages over free enzymes, such as
increased stability, localization, and retention of the molecules at the material surface, which enables
easier handling, repeated use, and decreased cost. Other important advantages of using therapeutic
immobilized enzymes are the prolonged blood circulation lifetime without the loss of specific
activity9 and the lower immunogenicity.11,137 This advantage is particularly important for delivering
enzymes or other biomolecules and may constitute an alternative and suitable method for the
enzyme replacement therapy. However, some limitations have been attributed to the use of immo-
bilized enzymes in biomedical applications, such as mass transfer resistances (substrate in and
product out), adverse biological responses of enzyme support surfaces (in vivo or ex vivo), fouling
by other biomolecules, greater potential for product inhibition, and sterilization difficulties.126,137
Although the preparation of sterile immobilized enzyme systems may be complex, sterilization
may be achieved by filtrating all the reagents and protein solutions through 0.2-mm filters and
working under aseptic conditions.
A very important issue regarding the use of enzymes or other products derived from biological
or biotechnological processes in medical applications is to ensure that these therapeutic products
do not contain any pyrogenic material, toxins, or infectious agents able to cause harmful effects.138
For that, it is necessary to perform a complete examination of the products to test their safety in
terms of local tolerance, toxicity, carcinogenicity, and immunogenicity, among other pharmacolog-
ical safety tests.138,139 Taking into account the diversity in the range of products and the uncertainty
about the regulatory status of some of them, it is necessary to design safety evaluation programs
to provide useful information to the responsible of clinical trials and to ensure patient safety.
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17.4 CONCLUSIONS AND FUTURE PERSPECTIVES
Enzyme instability, combined with the high cost associated with their isolation and purification,
had been restricting the general use of therapeutic enzymes on a clinical basis. With the advances
made in recombinant DNA technology, it is possible, by means of using adequate expression
systems, to put available in larger quantities many enzymes, both for the assay of metabolites and
for enzyme replacement therapy. The immobilization of enzymes on support materials had con-
tributed largely to the success of diagnosis and enzyme therapy approaches.
The recent progress in biological science had revealed many types of therapeutic proteins able
to regulate various cell functions. On the other hand, the development of new immobilization
strategies, such as selective immobilization of proteins to self-assembled monolayers presenting
active site-directed capture ligands140 or protein immobilization within specific locations (protein
patterning),82 may constitute the basis of future immobilization methods. This is particularly
important for biomedical applications where it is necessary to control the densities of immobilized
proteins, the binding strength, and, most important, their binding orientation. The success of
therapeutic agent delivery strategies will be mainly dependent on the developments in these
research fields.
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